Merck & Co., Inc. (0QAH.L)
| Previous close | 89.51 |
| Open | 92.36 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 89.12 - 89.48 |
| 52-week range | 89.12 - 89.48 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | 0.16 |
| EPS (TTM) | 5.59 |
| Earnings date | 27 Oct 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
RAHWAY, N.J. & MIAMI, October 06, 2022--Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
- Business Wire
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
RAHWAY, N.J., September 29, 2022--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Court of Appeals for the Federal Circuit ruled in favor of the company in a patent challenge brought by Mylan Pharmaceuticals, Inc. (now Viatris) related to sitagliptin dihydrogen phosphate, an active ingredient in JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin hydrochloride) and JANUMET® XR (sitagliptin and metformin hydrochloride extended-release
- Business Wire
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
RAHWAY, N.J., September 29, 2022--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, October 27. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook.
